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Abstract
In the past decade, we have witnessed a revolution in osteo-
porosis diagnosis and therapeutics. This includes enhanced
understanding of basic bone biology, recognizing the severe
consequences of fractures in terms of morbidity and short-term re-
fracture and mortality risk and case finding based on clinical risks,
bone mineral density, new imaging approaches, and contributors
to secondary osteoporosis. Medical interventions that reduce
fracture risk include sufficient calcium and vitamin D together with
a wide spectrum of drug therapies (with antiresorptive, anabolic,
or mixed effects). Emerging therapeutic options that target
molecules of bone metabolism indicate that the next decade
should offer even greater promise for further improving our
diagnostic and treatment approaches.
Introduction
In the past decade, we have witnessed a revolution in under-
standing bone biology. Major progress has also been achieved
in fracture risk estimation and prevention of fractures. How
does this progress translate into daily clinical practice? First,
case finding of subjects at highest risk for fractures is now
possible at the individual patient level, using clinical bone- and
fall-related risk factors, with and without bone mineral density
(BMD). Second, prevention of vertebral and nonvertebral
fractures, including hip fractures, is now possible by optimizing
calcium homeostasis and by appropriate medication in well-
selected patients with a high risk of fracture. Recent studies
indicate new possibilities for case finding, such as in vivo
structural analysis of bone microarchitecture, and new
molecular targets to rebalance bone remodeling. Here, we
review recent progress in case-finding strategies and in the
evidence that the risk of first and subsequent fractures can be
prevented in daily clinical practice.
The Fracture Risk Assessment Tool for
calculating the individual 10-year fracture risk
The clinical expression of osteoporosis is a fragility fracture,
but bone loss in and of itself is asymptomatic, which has led
to the description of osteoporosis as a ‘silent thief’. The
asymptomatic nature of bone loss suggests that osteoporosis
cannot be detected before a fragility fracture occurs, unless
BMD is measured. Indeed, BMD is related to bone strength
and low BMD is a major risk factor for fractures. However,
most patients presenting with a fracture do not have BMD-
based osteoporosis, defined according to the World Health
Organization (WHO) definition as a T score of –2.5 or below
[1]. Many qualities of bone, other than low BMD, are involved
in fracture risk such as structural and material components of
bone and the cellular activities and molecular signals that
regulate lifelong bone remodeling under control of
mechanical load, hormones, growth factors, and cytokines.
Some of these characteristics of bone are measurable in
clinical practice (for example, BMD, bone size, vertebral
deformities and fractures, and markers of bone turnover), but
many are not (for example, material properties) or are just
evolving (for example, microarchitecture by microcomputer
tomography or magnetic resonance imaging). In addition, and
independent of bone-related risks, extraskeletal risk factors
such as fall risk contribute to fracture risk and are present in
the majority of patients older than 50 years presenting with a
clinical fracture [1].
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Large-scale prospective population studies have enabled the
specification of clinical risk factors for fractures that are
independent of low BMD and have allowed quantification of
their relative risks (RRs) for predicting fractures. Thus, many
aspects of osteoporosis and fracture risk are clinically recog-
nizable (such as age, gender, and body weight), even before
a first fracture has occurred. However, RRs are difficult to
apply in daily clinical practice since their clinical significance
depends on the prevalence of fractures in the general
population. From this observation and for the purpose of
clinical application, the concept of the absolute risk (AR) of
fractures has emerged and refers to the individual’s risk for
fractures over a certain time period (for example, over the next
10 years) [2].
During the last decade, the development of the Fracture Risk
Assessment Tool (FRAX) algorithm as a clinical tool for
calculation of fracture risk in the individual patient is a major
achievement in the field of case finding [2,3]. The FRAX is
based on large-scale prospective population-based studies
and includes age, gender, body weight and body mass index,
a history of fracture, hip fracture in parents, current smoking,
excessive alcohol intake, rheumatoid arthritis, glucocorticoid
use, and other forms of secondary osteoporosis (Table 1).
The WHO developed FRAX especially for primary care
physicians for calculating the individual 10-year risk of hip
and major fractures (defined as clinical spine, forearm, hip, or
humerus fracture) in daily practice in women and men, based
on the above-mentioned clinical risk factors, with and without
results of BMD measurement in the femoral neck.
Strengths of the Fracture Risk Assessment Tool
FRAX is based on a large sample of primary data of
prospective population studies and takes into account
variability in fracture probability between geographic regions.
FRAX should not be considered a gold standard but rather a
platform technology and provides an aid to enhance patient
assessment. FRAX can be integrated in clinical practice in
many countries worldwide, both in women and men. FRAX is
therefore likely to become, in many countries, the most
popular instrument for identifying women and men at highest
risk for fractures.
FRAX has been included in guidelines as a tool for case
finding for identifying postmenopausal women at high risk for
fractures, for selecting subjects to measure BMD, and for
treatment decisions. The National Osteoporosis Foundation
(NOF) in the US and the National Osteoporosis Society
(NOS) in the UK have recently updated their guidelines on
postmenopausal osteoporosis in this context (Figure 1) [4,5].
These groups have integrated FRAX and BMD for case
finding of individuals at high risk for fracture and for treatment
decisions. Both sets of guidelines make a clear distinction
between postmenopausal women with and without a fracture
history. This is a major step forward in the clinical applicability
for postfracture treatment in patients presenting with a
fracture. Based on the fracture risk profile, the NOS, together
with the National Osteoporosis Guideline Group (NOGG)
and the Royal College of Physicians, determined treatment
thresholds at which fracture prevention became cost-effective
(Figure 2) [2,5].
Postmenopausal women with a history of fractures
The NOS advocates drug treatment in all postmenopausal
women with a history of any fragility fracture (defined as distal
radius, proximal humerus, spine [including morphometric
vertebral fracture], pelvis [pubic rami], tibia, and ankle) [5].
The NOF advocates drug treatment in postmenopausal
women with a vertebral or hip fracture (without need of BMD
or FRAX for decisions about pharmacotherapy), but after a
nonvertebral nonhip fracture, the NOF advocates performing
a dual-energy x-ray absorptiometry (DXA) measurement and
starting drug treatment in patients having osteoporosis and in
patients with osteopenia when FRAX indicates a 10-year
fracture probability of at least 3% for hip or at least 20% for
major fractures. Thus, in postmenopausal women with a
history of vertebral or hip fracture, neither set of guidelines
uses FRAX for decisions about drug treatment (and neither
does the NOS for after any fragility fracture), and both sets
consider such fracture history by itself as a starting point for
case finding and treatment decisions.
Table 1
Clinical risk factors and bone densitometry results that are




History of fracture after the age of 45 to 50 years
Parent with hip fracture
Current smoking
Alcohol intake of greater than 2 units per day
Glucocorticoid use
Rheumatoid arthritis
Other causes of secondary osteoporosis:
- Untreated hypogonadism in men and women, anorexia 
nervosa, chemotherapy for breast and prostate cancer, 
and hypopituitarism
- Inflammatory bowel disease and prolonged immobility (for 
example, spinal cord injury, Parkinson disease, stroke, 
muscular dystrophy, and ankylosing spondylitis)
- Organ transplantation
- Type I diabetes and thyroid disorders (for example, 
untreated hyperthyroidism and overtreated 
hypothyroidism)
Results of bone densitometry using dual-energy x-ray absorptiometry of
the femoral neck.Postmenopausal women without a fracture history
The NOS advocates applying FRAX (without BMD) in all
postmenopausal women. Women at high risk according to
FRAX without BMD are then considered candidates for drug
treatment. Women with an intermediate risk according to FRAX
without BMD are recommended to have a DXA measurement,
and when FRAX with BMD is above the intervention threshold
according to the NOGG, drug treatment should be considered.
The NOF advocates using DXA in all women older than
65 years and in postmenopausal women younger than
65 years in whom there is concern about their fracture risk
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Figure 1
Algorithms for case finding and drug treatment decisions in postmenopausal women with and without a history of fractures according to the
National Osteoporosis Foundation (NOF) in the US and the National Osteoporosis Society (NOS) in the UK. DXA, dual-energy x-ray
absorptiometry; FRAX, Fracture Risk Assessment Tool. *Previous fragility fracture, particularly of the hip, wrist and spine including morphometric
vertebral fracture. **Based on UK guidelines by NOGG.based on the presence of clinical risk factors. This approach
suggests that all postmenopausal women under 65 years of
age should be clinically classified as having at least one of
the risk factors of FRAX. Treatment is then recommended in
patients with osteoporosis, in patients with osteopenia when
the FRAX indicates a 10-year risk of greater than 3% for hip
fractures or greater than 20% for major osteoporotic
fractures, and in other patients considered at high risk (on
glucocorticoids, total immobilization). These upgraded guide-
lines indicate that FRAX is an emerging tool in clinical
decision making about case finding, selecting patients for
DXA, and treatment decisions in postmenopausal women
without a fracture history. Patients with a fracture are con-
sidered at high enough risk to make treatment decisions
without additional need for using FRAX. It is expected that
FRAX will also be helpful in designing fracture prevention
studies and in reimbursement issues. In a study from
Switzerland, profiles of patients at increased probability of
fracture beyond currently accepted reimbursement thresholds
for bone BMD measurement by DXA and osteoporosis
treatment were identified and constitute an additional group
of patients in whom treatment should be considered [6].
Limitations of the Fracture Risk Assessment Tool
In spite of its solid scientific basis and clinical attractiveness,
FRAX has several limitations, as acknowledged by the
authors (Table 2) [2]. Meanwhile, FRAX has been integrated
in guidelines/guidance in the US, UK, Europe, Canada,
Germany, and Japan [2], but with different approaches for
diagnostic and treatment thresholds, as shown above for the
NOS and the NOF [4,5]. Fracture reduction has been
demonstrated in randomized controlled clinical trials in
patients selected on the basis of the presence of a
morphometric vertebral fracture, hip fracture, or a low BMD,
but not on the basis of FRAX. Therefore, of great interest is
the finding that fracture reduction was greater at higher
fracture probabilities based on FRAX, with or without BMD.
Antifracture efficacy was evident when baseline fracture
probabilities for major fractures were greater than 20% in
the clodronate trial (in preventing major fractures) [7] and
greater than 16% in the bazedoxifene trial (in preventing
clinical fractures), irrespective of whether BMD was used in
the fracture calculation [2]. Further studies will be needed on
the ability of treatment to reduce fracture risk in subjects at
high risk for fractures based on FRAX in the absence of a
morphometric vertebral fracture, hip fracture, or a low BMD,
which is the case in most patients presenting with a
nonvertebral fracture. Decisions on treatment thresholds will
furthermore depend on factors related to health care
providers and patients and the willingness of society to
reimburse treatment as health economic aspects are
becoming increasingly important to determine the cost-
effectiveness of treatment. Meanwhile, the NOGG of the UK
has indicated FRAX-based thresholds  for measuring BMD
and for treatment decisions, with and without BMD (Figure 2).
The management algorithms proposed by the NOGG are
underpinned by a health economic analysis applied to the
epidemiology of fracture in the UK.
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Figure 2
Assessment and intervention thresholds based on the 10-year risk of major fracture, as proposed in the UK [2]. BMD, bone mineral density. With
kind permission from Springer Science+Business Media [5].Fall-related risks were explicitly excluded from the FRAX
calculations but were recognized as risks for fractures
independently of bone-related risks, especially for non-
vertebral fractures such as hip fractures. More than 80% of
women and men presenting with a clinical fracture to the
emergency unit have, beside bone-related risks, one or more
fall-related risks and have, independently from BMD, a
fourfold increased risk of a fall history during the previous
year [1]. In an integrated bone- and fall-related risk evaluation
tool for the estimation of the 5- and 10-year ARs for fractures
in patients using glucocorticoids, a history of falls had a
greater impact on fracture risk than any other evaluated risk,
and its contribution to fracture risk was similar to, and inde-
pendent of, using a high dose of glucocorticoids (prednisone
greater than 15 mg/day) [8]. Thus, with FRAX, fracture risk
calculation could be underestimated in patients with fall risks.
Subsequent fractures and postfracture
mortality cluster in time: the need for
immediate clinical attention in patients
presenting with a fracture
A history of nonvertebral fracture is associated with a
doubling of the risk of a subsequent fracture, and the
subsequent fracture risk is even quadrupled after a vertebral
fracture. However, this re-fracture risk is not constant over
time and is driven by the high, threefold to fivefold increase in
the years immediately after a first fracture, followed by a
gradual waning later on (Figure 3) [9]. This has been shown
for repeat morphometric vertebral fractures, subsequent
clinical spine, forearm, and hip fractures after hospitalization
because of a vertebral fracture, repeat low trauma fractures in
subjects older than 60 years, repeat clinical vertebral and
nonvertebral fractures from menopause onwards, and repeat
hip fractures [9-12]. As a result, it has been shown in long-
term follow-up studies that 40% to 50% of all subsequent
fractures occur within 3 to 5 years after a first fracture. The
clinical implication is that patients older than 50 years
presenting with a fracture need immediate attention to reduce
the risk of a subsequent fracture. This is a situation in which it
is important to take immediate action in fracture patients,
such as a fracture liaison service and other initiatives in the
field of postfracture care [13,14]. It also indicates that, in
such patients, treatment that has been shown to reduce
fracture risk within the short term should be started [15].
An increased risk of mortality has been found after hip,
vertebral, and several nonhip, nonvertebral fractures [16]. As
for subsequent fracture risk, this increase in mortality is
higher immediately after fracture than later on. In women and
men older than 60 years, nearly 90% of excess deaths
related to fracture over the 18 years of observation occurred
in the first 5 years. Of the 5-year excess mortality, hip,
vertebral, and nonhip, nonvertebral fractures were each
associated with approximately one third of deaths. The major
causes of death were related to cardiovascular and
respiratory comorbidity [16].
Assessment of vertebral fractures: an
opportunity to identify high-risk patients
Vertebral fractures are a special group of fractures.
Morphometric vertebral fractures are the most frequent
fractures in women and men older than 50 years [17] and
their presence is a strong predictor of future vertebral, non-
vertebral, and hip fracture risk [18]. Clinical vertebral
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Table 2
Limitations of the Fracture Risk Assessment Tool for case finding
- Factors not included in FRAX:
￿ The ‘dose effect’ of some risk factors
￿ Glucocorticoid use (dose and duration)
￿ Characteristics of previous fractures (location, number, and severity)
￿ Fall risks
￿ Vitamin D deficiency
￿ Fluctuation over time of subsequent fracture
￿ Markers of bone formation and bone resorption
￿ How to identify patients with a vertebral fracture
￿ Which laboratory tests are indicated (and in whom) to exclude secondary osteoporosis
- FRAX is applicable only in untreated patients.
- Inclusion of BMD results is limited to results of BMD in the femoral neck. However, total hip BMD can be used interchangeably with femoral 
neck BMD in women, but not in men.
- FRAX does not indicate which intervention is indicated at which level of 10-year fracture risk of hip or major fractures (for either 
nonpharmacological or drug treatment). 
BMD, bone mineral density; FRAX, Fracture Risk Assessment Tool.fractures represent one out of three to four morphometric
vertebral fractures and represent less than 10% of all
fractures in patients presenting with a fracture to the
emergency department [1]. Most morphometric vertebral
fractures are not diagnosed until clinically suspected (for
example, significant height loss, hyperkyphosis, protruding
abdomen, rib-iliac crest distance of less than 2 cm, and acute
or chronic back pain) and imaging by x-ray is performed. But
even when lateral x-rays of the spine are available, vertebral
fractures are often missed [18,19].
Vertebral fracture assessment (VFA) is a new method to
evaluate the presence of morphometric vertebral fractures
and deformities using x-ray absorptiometry (Figure 4) [19].
With appropriate DXA devices, VFA can be performed at the
occasion of a bone densitometry. Advantages are its low
irradiation, the availability of semiautomatic image analysis
tools to assist in measuring vertebral shapes of the individual
vertebrae, its plan-parallel projection, and its high negative
predictive value. Disadvantages include difficulties in measur-
ing upper thoracic vertebrae due to overlying soft tissue and
ribs.
The prevalence of previously unknown morphometric verte-
bral fractures has been studied in various at-risk populations.
In a recent study of women and men presenting with a
nonvertebral fracture, one out of four had a prevalent morpho-
metric vertebral fracture on VFA that was not recognized
previously [14]. In one other study, the prevalence of
morphometric vertebral fractures was 21% in postmeno-
pausal women with osteopenia [20]. The authors concluded
that the use of VFA contributed to better define the fracture
risk in patients presenting with a nonvertebral fracture and in
women with osteopenia and contributed to treatment
decisions by identifying patients at high risk of fractures in the
absence of BMD osteoporosis. VFA also helps to select
patients in whom x-rays of the spine are indicated to
differentiate changes in shape from normal variations and
diseases such as Scheuermann disease, pathologic
fractures, bone remodeling in the context of osteoarthritis,
and developmental short vertebral height [19]. According to
the International Society of Clinical Densitometry (ISCD),
additional x-ray imaging is needed in cases of two or more
mild (grade 1) deformities without any moderate or severe
(grade 2 or 3) deformities, when lesions in vertebrae cannot
be ascribed to benign causes, or when vertebral deformities
are found in a patient with a known history of a relevant
malignancy [19]. In patients with BMD-diagnosed osteo-
porosis, a baseline VFA is not necessary for treatment
decisions but can be helpful to identify during follow-up
whether a vertebral fracture is new or old [15]. Indications for
VFA according to the ISCD are shown in Table 3 [19].
Differential diagnosis in patients with
osteoporosis or a fragility fracture or both
Randomized controlled trials on fracture prevention in post-
menopausal women exclude patients with secondary osteo-
porosis, except in studies in glucocorticoid users. However,
patients with BMD-diagnosed osteoporosis or presenting
with a clinical fracture or both often have contributors to
secondary osteoporosis. FRAX includes a long list of causes
of secondary osteoporosis that contribute to fracture risk
independently of other clinical risks and BMD (Table 1) [2,3].
Differential diagnosis in the context of case finding therefore
includes a thorough medical history and clinical examination.
Based on FRAX, laboratory investigations can contribute to
case finding, but FRAX does not give instructions on how to
exclude other contributors to secondary osteoporosis that are
frequently found in patients with osteoporosis or fractures or
both [21,22]. In patients with BMD-based osteoporosis or
presenting with a clinical fracture or both, diagnostic evalua-
tion is necessary and should include serum 25-(OH)D3,
calcium, creatinine, thyroid-stimulating hormone, parathyroid
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Figure 3
Risk of first and subsequent fracture over time. (a) Percentage of all
first fractures from menopause onwards (grey line) and fractures
subsequent to initial fractures (black line). (b) Relative risk of all
subsequent fractures calculated as a mean from the time of first
fracture (grey line) and per separate year of follow-up after a first
fracture (black line).hormone (PTH), testosterone (in men) and, of 24-hour urine,
calcium and creatinine [21-23]. According to the clinical
picture and suspicion, other serum measurements such as
plasma cortisol, hemoglobin, white blood cell count,
serum/urine protein electrophoresis, and selected other
evaluations looking for secondary causes are indicated.
Only limited studies about the prevalence of secondary
osteoporosis in daily practice have been published during the
last decade. In patients referred for DXA in the clinical
context of an osteoporosis clinic, contributors to secondary
osteoporosis were already documented in one out of three
postmenopausal women with osteoporosis [21]. In the group
of otherwise presumably healthy women, previously undiag-
nosed contributors were found in an additional 30% of
women [21]. In women and men presenting with a clinical
fracture at the emergency unit and having BMD osteoporosis,
42% had contributors to secondary osteoporosis, mainly
vitamin D deficiency [22].
Vitamin D deficiency is endemic worldwide [24] but is not
included in the FRAX algorithm. Vitamin D deficiency was
found to be the main contributor to secondary osteoporosis
in postmenopausal women with BMD osteoporosis [21], in
women and men presenting with a clinical fracture and having
BMD osteoporosis [22], and in patients presenting with a hip
fracture [25]. Recent data indicate that vitamin D is an
independent risk for fractures [26], and meta-analyses
indicate that correction of vitamin D deficiency results in a
decreased fall and fracture risk [27,28], but the effects
depend on the dose of vitamin D and the target population
[29]. Frail older people confined to institutions may sustain
fewer hip fractures if given vitamin D with calcium. Vitamin D
alone is unlikely to prevent fracture [30].
It is still a matter of debate which dose of vitamin D3 (or
potentially D2) supplementation is necessary/optimal, taking
into account baseline vitamin D status and the desired serum
levels to be achieved by supplementation [31-33]. Clearly, an
intake of 400 IU/day is not sufficient [31-34]. A daily intake of
800 to 1,600 IU in healthy adults will increase serum levels
above 75 nmol/L in half of the population [33]. Others
suggest that 1,000 to 1,200 IU/day is necessary in addition
to typical food and cutaneous inputs to achieve a target
serum level of 80 nmol/L (32 ng/mL) [31].
Lifelong milk intake is not related to fracture risk [35], but in
several reviews, the necessity of addition of calcium to
vitamin D for fracture prevention was stressed and a dose of
1,000 to 1,200 mg/day was advocated [34,36]. However, in
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Figure 4
Example of using dual-energy x-ray absorptiometry technology for vertebral fracture assessment.studies published in 2008, supplements of 1,000 mg
calcium/day in healthy postmenopausal women [37] and
healthy men [38] with a mean baseline calcium intake of
800 mg/day were associated with an increased risk of
vascular events, including myocardial infarction. These
studies raised considerable controversy and suggested the
need for further research [39]. In this context, it is reassuring
that, when intake of vitamin D3 is sufficient, the need for
calcium intake is considered to be lower [32,40-42]. Indeed,
if dietary calcium is a threshold nutrient, as suggested by
Heaney [41], then the threshold for optimal calcium absorp-
tion may be at a lower calcium intake when vitamin D nutrition
is higher. Until well-designed studies address the current
uncertainties, the possible detrimental effect (for example,
hypercalcemia and its complications) of higher-than-recom-
mended calcium intake should be balanced against the likely
benefits of calcium on bone, particularly in older women [43].
It should be noted that all clinical trials with drug therapy for
osteoporosis (bisphosphonates and so on) have been con-
ducted with the concomitant use of calcium and vitamin D
supplementation.
It is generally considered that secondary causes of osteo-
porosis are more common in men than women, with the
exception of hormone deficiency, which is characteristic after
menopause, whereas andropause, depending on its
definition, is found in only a subgroup of older men or men
with osteoporosis [44]. Hypogonadism resulting from the
treatment of breast and prostate cancer is recognized as an
emerging clinical problem [45]. Cancer treatment-induced
bone loss with adjuvant endocrine therapy with an aromatase
inhibitor or androgen deprivation can be considered a risk
factor for the development of osteopenia, osteoporosis, and
bone fracture, which can be mitigated by appropriate
bisphosphonate therapy [45]. Other, less common, risk
factors for osteoporosis and fractures but commonly present
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Table 3
Indications for vertebral fracture assessment using x-ray absorptiometry [19] 
1. Postmenopausal women with low bone mass (osteopenia) by BMD criteria plus one of the following:
- Age of greater than or equal to 70 years.
- Historical height loss of greater than 4 cm.
-  Prospective height loss of greater than 2 cm.
-  Self-reported prior vertebral fracture (not previously documented).
-  Two or more of the following:
Age of 60 to 69 years.
Self-reported prior nonvertebral fracture.
Historical height loss of 2 to 4 cm.
Chronic systemic diseases associated with increased risk of vertebral fractures (for example, moderate to severe COPD, 
seropositive rheumatoid arthritis, and Crohn disease).
2. Men with low bone mass (osteopenia) by BMD criteria plus one of the following:
-  Age of 80 years or older.
-  Historical height loss of greater than 6 cm.
-  Prospective height loss of greater than 3 cm.
-  Self-reported vertebral fracture (not previously documented).
-  Two or more of the following:
Age of 70 to 79 years.
Self-reported prior nonvertebral fracture.
Historical height loss of 3 to 6 cm.
On pharmacological androgen deprivation therapy or following orchiectomy.
Chronic systemic diseases associated with increased risk of vertebral fractures (for example, moderate to severe COPD, 
seropositive rheumatoid arthritis, and Crohn disease).
3.  Women or men on chronic glucocorticoid therapy (equivalent to 5 mg or more of prednisone daily for 3 months or longer).
4.  Postmenopausal women or men with osteoporosis by bone density criteria (total hip, femoral neck, or lumbar spine T score of not more than 
–2.5) if documentation of one or more vertebral fractures will alter clinical management.
BMD, bone mineral density; COPD, chronic obstructive pulmonary disease.in patients with low BMD or presenting with a fracture and
that are not part of FRAX include the use of medications (for
example, anticonvulsants, primary hyperparathyroidism, renal
insufficiency, gastrectomy, Cushing syndrome, dementia, and
chronic pulmonary and/or liver diseases).
Fall prevention measures
Vitamin D supplements decrease the risk of falls, as
discussed above. Extraskeletal measures that are advocated
in guidelines include avoidance of immobility, stimulation of
weight-bearing exercise, and physiotherapy. Recent system-
atic reviews indicate that these measures still need more
research to specify their role in the prevention of fractures.
Fall prevention interventions that are likely to be effective in
older people are now available [46]. Less is known about
their effectiveness in preventing fall-related injuries, and no
data that fall prevention decreases the risk of fracture are
available. Exercise interventions reduce the risk and rate of
falls in older people living in the community [47]. The role of
hip protectors remains controversial in light of low
acceptance and low acceptability and adherence due to
discomfort and practicality [48,49].
Advances in osteoporosis pharmacotherapy:
more than a decade of progress
Beyond the need for sufficient calcium, vitamin D, and
exercise, the past decade has seen an emergence of new
data supporting a growing armamentarium of therapeutics for
osteoporosis. Pharmacological therapies useful in the preven-
tion and treatment of osteoporosis affect bone remodeling by
either inhibiting bone resorption or enhancing bone formation.
The majority of the agents currently licensed in both the US
and other countries inhibit bone resorption. Recombinant
PTH (teriparatide), on the other hand, is a bone anabolic
agent. Strontium ranelate has a dual effect on bone
remodeling: it stimulates bone formation and inhibits bone
resorption, as shown in animal models, but is not available in
the US. Despite an increasing number of well-designed
studies providing evidence for pharmacotherapies in redu-
cing primary or secondary fracture risk, many high-risk
patients are not treated [50], and for patients who initiate
therapy, adherence to therapy is commonly below 50% at 1
to 2 years [51].
Estrogen
Estrogen has a direct effect on bone mass through receptors
on osteoclasts and other bone cells and it results in lowered
bone turnover and resorption. Observational studies have
suggested a 25% to 70% risk reduction for fractures
associated with the use of estrogen replacement therapy
(ERT) [52-55]. Results from the Women’s Health Initiative
(WHI), a study of over 16,000 postmenopausal women,
convincingly confirmed a significant risk reduction of hip
fractures attributed to combined conjugated equine estrogen
and medroxyprogesterone (RR = 0.66, 95% confidence
interval [CI] 0.45 to 0.98) [56] as well as estrogen alone in
those women who had undergone hysterectomy [57]. In
addition to its beneficial effects on bone, ERT raises high-
density lipoproteins and lowers low-density lipids in post-
menopausal women [58,59]. Although a number of obser-
vational studies, including the Nurses Health Study [60], have
reported a 35% to 80% reduction in cardiovascular events
and prolonged survival among women with coronary heart
disease compared with nonusers [61-65], results from the
WHI and other studies of both primary and secondary cardio-
vascular prevention refute this conclusion [56,62,66,67].
Data from the WHI found a nearly 30% increased risk of
coronary heart disease and an over 40% increased risk of
stroke.
Beyond heart disease, three significant concerns with
estrogen are an increased risk of thromboembolic events [68],
hyperplastic effects on the endometrium (potentially leading
to endometrial cancer), and a heightened risk for breast
cancer. The WHI [56] and other studies [69] have shown a
26% to 35% increased risk of breast cancer. Some [70], but
not all [71], studies suggest that invasive breast tumors that
develop among estrogen users have a more favorable
histologic prognosis and that lobular cancer is more common
than ductal cancer [72].
The decision to initiate ERT should be individualized and
based on a balanced assessment of risk and benefits by the
physician and patient [73,74]. Lower-dose estrogen can
increase bone mass, may have a lower adverse effect profile,
and raises interest in further study of this possible approach
[75,76]. The proven increased risks for breast cancer and
hypercoagulability and the higher risks of both primary and
secondary cardiovascular disease (at least among older
women) offset bone benefits and have substantially
diminished enthusiasm for long-term higher-dose estrogen
historically used by many patients. Although questions about
the relative benefit and risks of different estrogen types,
routes of administration (oral versus transdermal),
administration protocols (opposed by progestins versus
unopposed), and variable risk profiles based on a woman’s
age and comorbidities persist, current recommendations
support restricting the use of estrogen in most women to the
perimenopausal period [77,78] and not with the primary aim
to prevent fractures in the context of treatment of
osteoporosis. Furthermore, the growing array of alternative
bone-directed medications now available further restrict the
estrogen niche.
Selective estrogen receptor modulators
Selective estrogen receptor modulators (SERMs) are non-
steroidal synthetic compounds that have estrogen-like
properties on the bone and cardiovascular systems yet are
estrogen antagonists to the breast and, in some cases, the
endometrium. The first SERM developed both for breast
cancer prevention and for osteoporosis, raloxifene, is now
licensed in many countries for osteoporosis [79]. After 3
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Evaluation (MORE), a multicenter study of over 7,700 post-
menopausal women with at least one vertebral fracture or
osteoporosis on the basis of a T score of –2.5 or below,
60 mg/day of raloxifene reduced vertebral fracture risk by
30% [80]. This decline in fracture risk at the spine was of a
magnitude similar to that seen with more potent antiresorptive
agents such as the aminobisphosphonates and emphasized
the importance of attenuation of bone turnover, in addition to
effects on BMD, for fracture risk reduction [81,82]. Similar to
tamoxifen, the risk of invasive breast cancer was decreased
by 72% during the MORE study [83,84], particularly among
women with higher estradiol levels [85,86]. Hot flashes and
other menopausal symptoms may recur on raloxifene. Also
similar to estrogen, with raloxifene, there is an increase in
lower-extremity edema as well as a roughly threefold
increased risk of deep venous thrombosis [80]. Additional
SERMs, such as bazedoxifene and lasofoxifene, are under
development. Bazodoxifene decreases vertebral fracture risk
to a degree similar to that of raloxifene (approximately 40%
over a 3-year period [87]) and, in a post hoc analysis, reduced
the risk of nonspine fractures in a subgroup of patients with
high risk for fractures based on the FRAX algorithm [2].
Preliminary results from the PEARL (Postmenopausal
Evaluation And Risk reduction with Lasofoxifene) trial showed
significant reductions compared with placebo in vertebral and
nonvertebral (but not hip) fracture risk as well as in estrogen
receptor breast cancer with the 0.5 mg dose [88]. This is the
only SERM, to date, that has primary data on nonvertebral
fracture risk reduction. Of potential concern, a small rise in
overall mortality was reported in the 0.25 mg dose but not in
the 0.5 mg dose.
Calcitonin
Randomized controlled trials of both injectable [89-91] and
intranasal [92-95] calcitonin for treatment of established
postmenopausal osteoporosis have consistently shown either
stabilization of BMD or small, but significant, increases in
vertebral BMD of approximately 1% to 3% on 200 IU daily for
over 3 to 5 years. Beneficial BMD effects at the hip have not
yet been reported. Modest increases in vertebral BMD with
intranasal calcitonin are accompanied by significant declines
in biochemical measures of bone resorption [96]. A 5-year
multicenter study of 1,255 postmenopausal women showed
a 36% reduction in vertebral fractures in the 200 IU, but not
in the 100 or 400 IU, dosage group. Interpretation of study
results was further limited by an approximately 50% dropout
rate [97,98]. Nasal calcitonin is generally well tolerated, with
occasional rhinitis. Headache, flushing, nausea, and diarrhea
have been reported more commonly with subcutaneous
rather than with intranasal calcitonin. On the basis of data
that are somewhat weaker than those of osteoporosis drugs
(including the absence of data on hip or nonvertebral fracture
risk reduction) along with emerging new therapeutic agents,
calcitonin has been relegated to a second- or third-line agent
for osteoporosis prevention and treatment.
Bisphosphonates
Bisphosphonates are potent inhibitors of bone resorption and
fractures when administered orally or by intravenous infusion
[99]. Variations in the structure of the amino side chains of
these drugs affect their pharmacological activity. All oral
bisphosphonates are poorly absorbed, with bioavailability of
less than 1%. These agents bind tightly to hydroxyapatite
crystals of bone, where they have a variable but generally
long skeletal retention (approximately 10 years for alendro-
nate). Over prolonged administration, a regional paracrine
effect of continuously deposited and recycled bisphos-
phonates may partially account for a lack of rapid loss of
BMD gains at some, but not all, skeletal sites when these
agents are discontinued [100-102]. The nitrogen-containing
bisphosphonates (that is, alendronate, risedronate, and
zolendronate) have variable affinity for bone and function as
antiresorptive agents by variable enzyme inhibition, impairing
cholesterol metabolism of the osteoclast and leading to
cytoskeletal alterations and premature osteoclast cell death
via apoptosis [103,104].
As a class, oral bisphosphonates may lead to gastrointestinal
(GI) intolerance, particularly at low pH [105]. Most reported
GI symptoms have been nonulcer dyspepsia, and in most
clinical trials, there have not been significant differences
between those exposed to bisphosphonates and those
receiving placebo [106,107]. There have been rare reports of
severe esophagitis [108] and case reports of esophageal
cancer in patients taking oral bisphosphonates [109]. Some
small studies suggest that GI side effects may be fewer with
risedronate than alendronate [110].
The most common bisphosphonates licensed and used
internationally are alendronate, risedronate, ibandronate, and
zoledronic acid. These drugs are used in osteoporosis, Paget
disease, myositis ossificans progressiva, heterotopic ossifica-
tion, multiple myeloma, other malignancies with bone
metastasis, and hypercalcemia. Alendronate, risedronate, and
zoledronic acid have all been shown to improve BMD among
patients receiving glucocorticoids [111-114].
Alendronate was the first aminobisphosphonate approved by
the US Food and Drug Administration for the treatment and
prevention of osteoporosis. Postmenopausal women
receiving 10 mg/day of alendronate showed a lumbar spine
BMD increase of 7% to nearly 9% over a 2-year period
[115,116]. Smaller, but still significant, changes were seen at
the femoral neck and trochanter. In early postmenopausal
women, 5 mg/day of alendronate prevented the loss of BMD
at the spine, hip, and total body [117]. In a separate study,
the 5 mg/day dose prevented bone loss to nearly the same
extent as an estrogen-progestin combination (estrogen effect
was 1% to 2% greater than 5 mg) [118]. Increases in spinal
BMD with alendronate continue for up to 7 years of daily
therapy [119]. Daily alendronate has a similar benefit and
adequate tolerability even among older female residents of
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alendronate has greatly exceeded daily administration based
on BMD efficacy, improved ease of use, and tolerability that is
equivalent to or better than daily therapy [121,122]. Among
2,027 older women with at least one prior vertebral fracture
and low femoral neck BMD in the Fracture Intervention Trial
(FIT), alendronate had significant 47% and 51% reductions in
morphometric vertebral and hip fractures, respectively [123].
In FIT subjects without prevalent vertebral fractures, alendro-
nate 10 mg decreased radiographic vertebral fractures by
44% [124]. A multinational study of alendronate similarly
identified a 47% risk reduction for nonvertebral fractures
[125]. A long-term extension to the FIT study found that, with
the exception of clinical vertebral fractures, fracture risk
reduction at other skeletal sites was statistically indistin-
guishable in those receiving 5 years on followed by 5 years
off of alendronate versus a full 10 years of therapy [100].
Further preliminary evaluation of these data has revealed that
women with a femoral neck BMD T score of –2.5 or below at
the 5-year mark had a higher risk of subsequent fractures
[126]. Thus, the decision about whether to stop therapy with
alendronate after a finite period of time is a topic of current
controversy and in need of additional scientific data. In
addition to prior duration of therapy, past adherence to
therapy informs the risk of subsequent fractures [127].
Combination approaches of bisphosphonates with either
estrogen or SERMs have shown equivalent or better BMD
than with either therapy alone [128,129], although concerns
of oversuppression of bone remodeling and potential risk of
inadequate repair of bone microdamage persist [130].
Alendronate can attenuate the loss of BMD seen after
stopping hormone replacement therapy [131].
Alendronate clinical trials have shown no significant increases
in serious adverse effects or significant GI adverse effects
between treatment groups and placebo [106,132]. In a study
of glucocorticoid-induced osteoporosis, there was a small
increase in nonserious upper GI adverse effects in those
taking 10 mg but not 5 mg or placebo [111]. Results of bone
histomorphometry indicate that alendronate decreases bone
turnover in a dose-dependent manner but does not impair
mineralization [121,133,134].
Risedronate is a pyridinyl bisphosphonate that increases
bone mass and prevents fractures [135]. In separate US
[136] and multinational [137] VERT (Vertebral Efficacy with
Risedronate Therapy) studies, 1,226 and 2,458 postmeno-
pausal women with at least one prior vertebral fracture were
treated with 5 mg of risedronate. Women receiving risedro-
nate experienced significantly fewer new vertebral (41% US
and 49% multinational) and nonvertebral (39% and 33%
reduction, respectively) fractures over a 3-year period [136].
In the Hip Intervention Program study, risedronate 5 mg
significantly reduced hip fractures among women with
confirmed low bone mass but not among those selected
primarily on the basis of fall risks without documented
osteoporosis [138]. Similar to alendronate, combined treat-
ment with risedronate and estrogen resulted in additive
improvement in BMD and further reduction in bone turnover
[139]. Although the increases in BMD seen with risedronate
were more modest compared with those of alendronate in
one head-to-head comparator study [140], a fairly similar
fracture effectiveness is believed to be due in part to the
decrease in bone resorption, as evidenced by significant
suppression of biochemical markers [141,142]. Risedronate
is taken daily, weekly, or (more recently) monthly and is
generally well tolerated, with no significant differences in
upper GI adverse events between those receiving placebo
and risedronate [136,143].
Ibrandronate either orally (daily or monthly schedules) or
intravenously successfully reduced markers of bone turnover,
increased BMD [144,145], and reduced fractures of the
vertebra (relative risk reduction [RRR] = 52%) [146].
Secondary analyses of persons in ibandronate studies with
initial BMD at or below –3.0 showed that ibandronate had a
protective effect on hip fracture risk reduction as well.
Zolendronic acid (zolendronate) is administered as a yearly
intravenous infusion and significantly reduced both vertebral
(RRR = 70%) and hip (RRR = 41%) fractures in a large
multinational study [147]. A subsequent study examined
women and men who had experienced a prior hip fracture
and showed a significant reduction in subsequent clinical
fractures along with a reduction in mortality [148]. Side
effects may include an acute-phase response with myalgias
and flu-like symptoms in 10% to 15% of patients receiving
their first dose. These symptoms most commonly resolve
within several days and are attenuated with acetaminophen,
prior oral bisphosphonates, and repeated doses of the
intravenous therapy. Patients receiving intravenous zoledronic
acid must have adequate renal function (creatinine clearance
of greater than 30 mL/minute) prior to getting this agent.
On the basis of largely uncontrolled reports of osteonecrosis
of the jaw and newer questions about atypical femoral
fractures, there is increasing scrutiny of particularly longer-
term therapy with bisphosphonates as a class [149]. Osteo-
necrosis of the jaw has been reported in an estimated 2% of
cancer patients receiving higher doses of predominately
intravenous bisphosphonates for patients with malignancies
in particular [150]. Cases also have been described in
patients receiving bisphosphonates for osteoporosis. Although
mechanisms are not confirmed for these two adverse
outcomes, if a relationship is supported by further studies,
this will have further impact on the idea of a ‘drug holiday’
[151].
In summary, there have been a large number of studies
documenting the efficacy of several bisphosphonates in
terms of BMD gains and, of more importance, with regard to
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class, bisphosphonates are the most efficacious anti-
resorptive agents currently available for bone. Despite a
significant duration of worldwide use of bisphosphonates, a
number of questions such as the necessary duration of
therapy, long-term safety, and use among women of child-
bearing potential as well as among children remain [152].
Parathyroid hormone
When bone is exposed to elevated PTH levels continuously
(e.g., hyperparathyroidism) it acts in a catabolic fashion. In
contrast, exogenously administered intermittent PTH is
anabolic stimulating skeletal remodeling and raising BMD
both in rodent models and in human studies [153,154]. PTH
(residues 1 to 34) (teriparatide) significantly decreased the
risk of vertebral (65% risk reduction in those on 20 μg/day)
and nonvertebral fractures and increased BMD at all sites
investigated, except for the radial shaft [155]. As a potential
explanation for initial decreases in cortical bone density at
sites such as the wrist, PTH initially increases intracortical
porosity. It also leads to periosteal new bone formation and
increases cross-sectional area, potentially increasing cortical
bone strength [156,157]. Teriparatide increases BMD in the
spine of men by nearly 6% [158]. There is an enhanced effect
on bone mass when PTH is sequentially followed by
alendronate [159] or estrogen [160]. When PTH is
compared directly with alendronate, there is a greater BMD
increase seen with PTH in postmenopausal [161] as well as
glucocorticoid-associated [162] osteoporosis. Although
BMD increases with PTH occur even in the presence of
potent antiresorptive agents such as alendronate [163],
antecedent oral bisphosphonates started concurrently with
PTH may attenuate bone mass improvement seen with PTH
[164,165]. PTH administered subcutaneously once a day has
been associated with asymptomatic hypercalcemia,
occasional nausea, and headache. Clinical trials of
teriparatide were terminated early by the finding of
osteosarcoma in Fisher rats [155]. Selective parathyroid
receptor agonists and antagonists are under investigation
and may play a future role in osteoporosis [166]. Due in part
to the development of osteosarcoma in Fisher rats in the
initial fracture trials (leading to their premature
discontinuation), teriparatide at 20 μg/day is recommended
for only a 24-month administration. It is used most commonly
in adults with severe osteoporosis, many of whom have had
fractures while on other antiosteoporotic agents or have had
intolerance to bisphosphonates.
Strontium ranelate
Daily intake of strontium ranelate has been shown to reduce
the risk of vertebral and nonvertebral fractures in post-
menopausal women with osteoporosis or a prevalent
vertebral fracture or both. In a post hoc analysis in women
over 74 years old with low BMD at the femoral neck, it
reduces the risk of hip fractures [167,168]. Fracture
reduction was still found after 5 years of treatment [169]. In a
post hoc analysis in women older than 80 years, strontium
ranelate reduced the risk of vertebral and nonvertebral
fractures [170]. Strontium ranelate prevented quality-of-life
impairment in postmenopausal women with established
vertebral osteoporosis [171].
Examples of new osteoporosis targets and
new mechanisms of action
Denosumab
The discovery of the receptor activator of the nuclear factor-
kappa B ligand RANKL/RANK/osteoprotegerin (OPG)
pathway has opened new ways to target osteoclastic bone
resorption. Clinical trials indicate that denosumab, a RANKL-
specific recombinant humanized monoclonal antibody, is
effective in suppressing bone resorption, resulting in an
increase in BMD in postmenopausal women with low BMD
[172-175]. The effect of denosumab on BMD and markers of
bone remodeling was more pronounced than with weekly
alendronate [176]. The effects on fracture reduction in
postmenopausal osteoporosis are awaited from the recently
finished FREEDOM (Fracture REduction Evaluation of
Denosumab in Osteoporosis Every 6 Months) study of nearly
8,000 women [177]. As compared with placebo, denosumab
reduced the risk of new radiographic vertebral fracture by
68%, with a cumulative incidence of 2.3% in the denosumab
group versus 7.2% in the placebo group (risk ratio 0.32, 95%
CI 0.26 to 0.41; P <0.001). Denosumab significantly
reduced the risk of hip fracture by 40% and also reduced
significantly the risk of nonvertebral fracture by 20%. There
was no increase in the risk of cancer, infection, cardio-
vascular disease, delayed fracture healing, or hypocalcemia,
and there were no cases of osteonecrosis of the jaw.
In clinical trials with denosumab, overall adverse events were
similar to placebo or comparators, indicating a favorable
safety profile in these diseases, which are, up until now,
available up to 4 years. Since the RANKL/RANK/OPG path-
way is involved in the development of the immune system,
data on long-term safety, particularly with respect to bacterial
infection and neoplasms, will be needed [172-176,178].
Catepsin K inhibition
Cathepsin K is the most abundant cysteine protease
expressed in the osteoclast and is believed to be instrumental
in the bone matrix degradation necessary for bone resorption.
Cathepsin K inhibitors represent a novel target for developing
agents to treat osteoporosis and other disorders
characterized by increased bone resorption [179].
Antisclerostin antibodies
The discovery that the Wnt signaling is a major pathway in
osteoblast activity has resulted in a revolution in our
understanding of the molecular mechanisms that are involved
in bone formation. Preclinical studies have shown that
sclerostin has a pivotal role as a negative regulator of bone
formation in the aging skeleton and, furthermore, suggest that
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promising new therapeutic approach for the anabolic
treatment of bone-related disorders, such as postmenopausal
osteoporosis [180].
Summary
In the past decade, we have witnessed a veritable revolution
in osteoporosis diagnosis and therapeutics. Much of the
success achieved has been motivated by an enhanced
understanding of basic bone biology, a topic reviewed in a
recent publication in the Arthritis Research & Therapy
anniversary series. While bone density maintains great
respect as one of the most valid and reliable measures of
fracture risk, a renewed appreciation for the importance of
other risk factors has led to new interest in AR models such
as FRAX. New imaging approaches, including lateral VFA,
have been added to the diagnostic armamentarium of bone
health evaluation in an effort to identify fractures earlier. There
is an increased appreciation of the severe consequences of
prevalent fractures, not only of the hip but also of the much
more common spine fractures. In particular, data substan-
tiating the heightened risk of short-term re-fracture have
increased the interest in secondary osteoporosis prevention.
As international focus on osteoporosis has grown,
accentuated diagnosis of alternate metabolic bone disorders
has followed, and astute clinicians must be aware that there
are many causes for low bone mass beyond osteoporosis.
The use of sufficient calcium and attention to adequate
vitamin D provide a necessary but often insufficient starting
place for osteoporosis prevention and treatment. Amino-
bisphosphonates, taken orally or intravenously, have become
the international mainstay of osteoporosis therapy. Questions
exist about the very-long-term safety and the potential need
for a drug holiday with some, if not all, of these compounds,
despite their common use. Alternate therapeutic approaches
that target suppression of bone resorption include historical
use of sex steroids, SERMs, and now, less commonly, nasal
calcitonin analogs. The mechanism of fracture reduction with
daily strontium ranelate needs further study. Teriparatide is
the first anabolic agent licensed for osteoporosis treatment
but it must be given as a daily subcutaneous injection and
used for a defined period of time. Therapeutic approaches on
the horizon include biologic agents targeting RANKL,
antibodies to sclerositin (a natural inhibitor of Wnt-mediated
bone formation), and approaches to inhibit proteolytic
enzymes such as catepsin K. While the past decade and a
half has been a very exciting time in clinical osteoporosis
care, the next decade should offer even greater promise for
further improving our diagnostic and treatment approaches.
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